Chimeric Antigen Receptor News and Research

RSS

CAR-T cells require an abundance of antigens to efficiently kill solid tumors

Immunotherapy, which harnesses the power of the body's immune system to fight disease, is gaining huge traction in treating cancer.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Researchers recently investigated the effect of infection with SARS-CoV-2 in patients with hematologic malignancies in minority populations.

21 Sep 2021

mRNA BNT162b2 vaccine safe in immunocompromised patients

The clinical trial showed that about 72.2% of immunocompromised patients had detectable antibodies against SARS-CoV-2.

14 Sep 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

CAR T cells expressing a natural RNA can activate the body’s own T cells against solid tumors

Chimeric antigen receptor (CAR) T cell therapy, which uses engineered T cells to treat certain types of cancers, has often been a challenging approach to treating solid tumors. CAR T cells need to recognize a specific target on cancer cells to kill them.

2 Sep 2021

CIRM approves a trio of awards for new stem cell-based projects

The governing Board of the California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to University of California San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis (ALS).

25 Aug 2021

UCLA scientists receive $1 million translational award to advance CAR T cell therapy for rare melanomas

Scientists Dr. Cristina Puig-Saus and Dr. Daniel Shin from the UCLA Jonsson Comprehensive Cancer Center have received a $1 million Translational Research Award from the U.S. Department of Defense Melanoma Research Program to help advance the use of chimeric antigen receptor, or CAR, T cell therapy as a treatment for people with acral, mucosal and uveal melanomas.

24 Aug 2021

Remote controlling of CAR-T cells with heat to precisely target tumors

A team of researchers led by bioengineers at the Georgia Institute of Technology is expanding the precision and ability of a revolutionary immunotherapy that is already transforming oncology. CAR T-Cell therapy has been hailed by patients, clinical-researchers, investors, and the media as a viable cure for some cancers.

18 Aug 2021

Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

Too many "exhausted" T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T cell therapy to do its job.

16 Aug 2021

Immunotherapy pairs ultrasound with immune cells to destroy tumors without toxic side effects

Bioengineers at the University of California San Diego have developed a cancer immunotherapy that pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue.

12 Aug 2021

Magnetic nanoparticles could enhance the efficacy of cancer immunotherapy

Boosting the function of natural killer cells with magnetic nanoparticles could make cancer immunotherapy more efficient.

6 Aug 2021

Metabolites of intestinal bacteria can positively influence the efficacy of tumor therapies

Certain metabolites of bacteria from the intestine make immune cells more aggressive as a new study conducted by scientists from Würzburg and Marburg reveals. The findings could help improve cancer therapies.

9 Jul 2021

Promising immunotherapy uses cancer-killing cells to destroy malignant tumors

Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors.

28 Jun 2021

Mayo Clinic researchers are working toward new CAR-T cell treatment for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma.

25 Jun 2021

Different comorbid conditions in COVID-19 patients can impact outcomes of positive PCR test results

New study results indicate that different comorbid conditions affecting individuals diagnosed with COVID-19 may impact how long they continue to receive positive SARS-CoV-2 polymerase chain reaction (PCR) test results.

17 Jun 2021

UC San Diego Health offers new immunotherapy treatment for multiple myeloma following FDA approval

Following the Food and Drug Administration's approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.

3 Jun 2021

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the world's largest clinical cancer research meeting.

1 Jun 2021

Novel approach to immunotherapy design could pave the way for new brain cancer treatments

A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma.

10 May 2021